TSW
AIMT

Thompson Siegel & Walmsley’s Aimmune Therapeutics AIMT Stock Holding History

Thompson Siegel & Walmsley’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,500
Closed -$179K – 906
2019
Q3 		$179K Buy
+7,500
New +$153K ﹤0.01% 396

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Thompson Siegel & Walmsley's AIMT Position: Q4 2019 in Review

Thompson Siegel & Walmsley sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 7,500 shares — an estimated $179K sold.

Thompson Siegel & Walmsley first reported a position in AIMT in Q3 2019 and held it in 1 quarter. The position peaked at $179K in Q3 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Thompson Siegel & Walmsley reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 7,500 Aimmune Therapeutics shares in Q4 2019, an estimated $179K.
  • Thompson Siegel & Walmsley first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Aimmune Therapeutics position peaked at $179K in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2019, filed 7 Feb 2020.